Tinted IOL demonstrates no significant changes in contrast and sensitivity

Article

Using an ultraviolet (UV) and blue-light filtering IOL presents no significant changes in scotopic and photopic contrast sensitivity, and colour perception.

Using an ultraviolet (UV) and blue-light filtering IOL presents no significant changes in scotopic and photopic contrast sensitivity, and colour perception, according to a study published in the Journal of Cataract and Refractive Surgery.

A prospective, randomized clinical study led by Dr Marcony R. Santhiago, Ophthalmology Department, University of São Paulo, Brazil, consisted of 60 eyes of 30 patients with bilateral visually significant cataract.

Each patient was fitted with a UV and blue-light filtering IOL in one eye (Acrysof Natural SN60AT) and a UV-only IOL (Acrysof SA60AT) in the fellow eye. The primary outcome measures included scotopic and photopic contrast sensitivity, colour vision and macular findings. All measurements were taken 5 years postoperatively.

The results demonstrated no significant optical coherence tomography (OCT) findings with regards to age-related macular degeneration. Also, there were no significant differences between the groups in terms of photopic and scotopic contrast sensitivity.

Additional studies are required to identify the potential advantages of using tinted IOLs for the protection of macular cells.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.